In this issue of Blood, Naudin et al investigated the functional relevance of PUMILIO 1 and 2 (PUM1 and PUM2), 2 highly conserved RNA-binding proteins (RBPs) and members of the PUM and FBF (PUF) family of posttranscriptional regulators, in early hematopoiesis and acute myeloid leukemia (AML). 2,3 Here, Naudin et al show that in both human and mouse models, knockdown (KD) of PUM1 and PUM2 is detrimental to HSPC expansion, leading to exit from the cell cycle and resulting in apoptosis in vitro. Engraftment and hematopoietic reconstitution were severely impaired in PUM1 KD or PUM2 KD human and mouse HSPCs, although homing was unaffected. 1 PUM proteins primarily exert posttranscriptional repression. They bind to the PUM-binding elements (PBEs) figure) . Previous works have linked FOXP1 to B-cell development and lymphoid malignancies as well as to neurogenesis.
8,9
A major finding of Naudin et al is the necessity of PUM1 and PUM2 as well as FOXP1 for primary human AML. 1 There could be great potential in exploring how crucial PUM1, PUM2, and FOXP1 are in various World Health Organization (WHO) AML subgroups. Based on the expression pattern of PUM1 and PUM2 in HSPCs, it is conceivable that leukemias with more "stemness" would show a higher degree of dependence on these proteins. The significant sensitivity of normal HSPCs to reduced levels of PUM1 and PUM2 could limit the efficacy of these proteins as therapeutic targets in AML. However, it is probable that certain subgroups of AML with high degrees of addiction to PUMs and FOXP1 function are especially susceptible to direct modulation as well as indirect therapies targeting their downstream pathways. Given the importance of PUMs in various somatic and germ line stem cells, 10 it is yet to be determined if direct targeting is the best therapeutic strategy.
In conclusion, Naudin and colleagues have for the first time linked the PUM RBPs to hematopoietic stem cell physiology and pathophysiology which promotes the expression of FOXP1 leading to the modulation of cell cycle inhibition and maintenance of both HSPC function and leukemic growth. 
FOXP1
Cell cycle PUM1 and PUM2 bind to the 39UTR of the FOXP1 transcript leading to increased FOXP1 protein levels. Elevated FOXP1 levels lead to reduction in p21 and p27 protein levels promoting cell cycle progression.
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RBCs pin platelets against the (thrombus) wall -----------------------------------------------------------------------------------------------------Kellie R. Machlus and Elisabeth M. Battinelli BRIGHAM AND WOMEN'S HOSPITAL; HARVARD MEDICAL SCHOOL
In this issue of Blood, Walton and colleagues reveal that elevated hematocrit enhances clot formation in vivo via increased platelet accumulation in a growing thrombus. 1 Although elevated hematocrit is an independent risk factor for cardiovascular disease, the specific contribution of an increased red blood cell (RBC) count to this etiology has remained elusive. This is largely due to complicating factors in diseases such as polycythemia vera (PV), where patients present with elevated hematocrit, but the specific role of RBCs in thrombotic risk is unclear. To circumvent these additional complications, Walton et al used a model where additional RBCs were infused into healthy mice and arterial clot formation was studied, thus isolating the contribution of the increased RBCs. Notably, the increased number of RBCs changed the hemodynamics of the blood around a growing thrombus, narrowing the near-wall, RBC-free zone (see figure) . This narrowed zone created a locale where platelets spend significantly more time in contact with the growing thrombus, increasing the probability of their binding and incorporation into the clot. Thus, elevated hematocrit, perhaps unexpectedly, was shown to enhance thrombotic risk by increasing the number of platelets incorporated into the thrombus.
T he prevalence of primary erythrocytosis in the United States has been reported to be 44 to 57 per 100 000.
2 The natural history of PV is complicated by thromboembolic events; patients with myeloproliferative disorders suffer from both arterial and venous thrombosis, which accounts for 40% of the mortality associated with these disorders. et al, a novel mechanism by which elevated hematocrit can lead to increased thrombosis risk has now been elucidated. The heightened hematocrit, which is the cornerstone of PV, results in redistribution of the blood cells within the circulatory bed. The RBCs push the platelets closer to the vessel wall, increasing the probability of adhesion and activation via von Willebrand factor and collagen, ultimately resulting in thrombotic manifestations. This novel finding is consistent with the etiology of thrombosis in PV, where an elevated platelet count does not explain thrombotic risk, and may finally provide an explanation for the mechanism of thrombosis in these patients. Arterial clots are dependent on platelets for their propagation; therefore, the article by Walton et al clearly establishes a mode by which elevated hematocrit increases the risk of arterial thrombotic events. However, patients with an elevated hematocrit can present with both arterial and venous thrombosis. 3, 5, 9 Therefore, what remains to be understood is whether similar principles apply to the formation of venous thrombi, which are not plateletdependent but instead largely RBC-and fibrinrich. Although the increased risk of venous thrombosis has also been tied to elevated hematocrit, it has been proposed that
